Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion type Assertion NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_head.
- NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion description "[We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAF(V600E) inhibitor PLX4032 or the MEK1/2 inhibitor AZD6244 in thyroid cancer cells harboring both the BRAF(V600E) and PIK3CA mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_provenance.
- NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion evidence source_evidence_literature NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_provenance.
- NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion SIO_000772 22090271 NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_provenance.
- NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion wasDerivedFrom befree-2016 NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_provenance.
- NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_assertion wasGeneratedBy ECO_0000203 NP939371.RAcPKLP6uvbr372e7rvGxHfLFOWkJq3qsgPYTD8nEavmA130_provenance.